Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Acquisitions & Divestments: 2020-2025

Historic Change in Acquisitions & Divestments for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $66.0 million.

  • Tango Therapeutics' Change in Acquisitions & Divestments fell 8.57% to $66.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $269.8 million, marking a year-over-year decrease of 17.76%. This contributed to the annual value of $327.8 million for FY2024, which is 7.29% down from last year.
  • As of Q3 2025, Tango Therapeutics' Change in Acquisitions & Divestments stood at $66.0 million, which was up 59.57% from $41.3 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $109.3 million for Q1 2024, and its period low was $30.4 million during Q3 2021.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $84.1 million (2023), whereas its average is $78.8 million.
  • In the last 5 years, Tango Therapeutics' Change in Acquisitions & Divestments skyrocketed by 106.98% in 2022 and then slumped by 32.93% in 2025.
  • Quarterly analysis of 5 years shows Tango Therapeutics' Change in Acquisitions & Divestments stood at $59.9 million in 2021, then skyrocketed by 36.94% to $82.0 million in 2022, then climbed by 3.79% to $85.1 million in 2023, then declined by 0.43% to $84.7 million in 2024, then decreased by 8.57% to $66.0 million in 2025.
  • Its last three reported values are $66.0 million in Q3 2025, $41.3 million for Q2 2025, and $77.8 million during Q1 2025.